International Symposium on: Cardiometabolic Risk and Vascular Disease - from Mechanisms to Treatment

RATIONALE
Cardiometabolic risk drives progression of atherosclerotic cardiovascular disease (ASCVD) and adversely
affects prognosis. Type 2 diabetes mellitus (T2D), chronic kidney disease (CKD), and ASCVD have common
risk factors including insulin resistance, hypertension, obesity, and dyslipidemia.
These conditions are still overlooked. Hence, the recognition of ASCVD and kidney disease in patients
with metabolic disorders and vice versa of metabolic disorders in patients with cardio-renal disease
remains an unmet need. Furthermore, several studies have reported substantial overlaps in the
pathophysiological mechanisms of these diseases and syndromes suggesting that a mechanism-based
approach to intervention may be useful across multiple disorders. Interventions used for the
management of patients with T2D, including sodium-glucose cotransporter 2 (SGLT-2) inhibitors,
glucagon-like peptide-1 receptor agonists (GLP-1 RA), selective mineral-corticoid receptor antagonists
(MRA), combined glucose-dependent insulinotropic peptide (GIP)/GLP-1 RA have demonstrated
beneficial effects in the prevention and treatment of CVD and CKD beyond their reductions in body
weight, HbA1c, and blood pressure.

Our symposium aims to explore the challenges and barriers in the recognition and treatment of patients
with multiple cardiometabolic comorbidities. It is designed to promote a working and learning
environment across specialty borders. Indeed, these patients require a comprehensive approach using a
combination of pharmacological and non-pharmacological approaches for prevention, diagnosis, and
treatment.

Prof. Francesco Cosentino
President of the Congress